Investor Presentaiton

sanofi Favorable PCV21 immune responses when compared to PCV20 Serotypes shared by PCV13, PCV20 and PCV21 IgG GMC ratio and difference % seroresponse vs PCV13 Post Dose 3: IgG GMC ratio Post Dose 3: Difference seroresponse Post Dose 4: IgG GMC ratio 1 3 4 5 HOH 6A 6B 7F 9V 14 18C 19A 19F 23F 0,25 HH 0,5 1 2 4 1 3 4 5 6A 6B 7F 9V 14 18C 19A 19F 23F -30 -10 10 134 5 6A 6B 7F 9V 14 18C 19A 19F 23F 30 0,25 0,5 PCV21 Phase II [NCT04398706] Seroresponse: IgG concentration ≥0.35 μg/mL for all serotypes PCV20 Phase III [NCT04382326] Seroresponse: IgG concentration ≥0.35 μg/mL for all serotypes except ≥ 0.23 µg/mL, 20.10 μg/mL and ≥ 0.12 µg/mL for serotypes 5, 6B and 19A respectively PCV21 selected formulation for next phase DISCLAIMER: data from separate studies should be interpreted with care. 64 Vaccines Investor Event 1 2 4 PCV21 Phase 2 PCV20 Phase 3 Registration criteria based on PCV13

View entire presentation